Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Health Policy ; 119(9): 1275-83, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26229022

ABSTRACT

OBJECTIVES: Corruption is one of several factors that may hinder the access to pharmaceuticals. Since Kuwait has the highest per-capita spending on pharmaceuticals in the region, we wanted to evaluate the level of transparency in its pharmaceutical sector using an established assessment tool adapted by the World Health Organization. METHODS: Standardized questionnaires were conducted via semi-structured interviews with key informants to measure the level of transparency in eight functions of the public pharmaceutical sector. RESULTS: The scores for the degree of vulnerability to corruption reflected marginal to moderate venerability to corruption for most pharmaceutical sectors. The perceived strengths included availability of appropriate laws, the presence of clear standard operating procedures, and the use of an efficient registration/distribution system. Weaknesses included lack of conflict of interest guidelines and written terms of reference, absence of pharmacoeconomic studies, and inconsistencies in law enforcement. CONCLUSIONS: Findings reveal that few functions of Kuwait pharmaceutical sector remain fairly vulnerable to corruption. However, the willingness of Kuwait Ministry of Health to adopt the assessment study and the acknowledgement of the weaknesses of current processes of the pharmaceutical sector may assist to achieve a transparent pharmaceutical system in the near future.


Subject(s)
Disclosure , Drug Industry , Advertising/ethics , Clinical Trials as Topic/ethics , Clinical Trials as Topic/standards , Conflict of Interest , Drug Costs , Drug Industry/economics , Drug Industry/ethics , Drug Industry/organization & administration , Drug Industry/standards , Humans , Kuwait
SELECTION OF CITATIONS
SEARCH DETAIL